Consider the inclusion of tisagenlecleucel for histologic transformation of follicular lymphoma (FL) to diffuse large B-cell lymphoma (DLBCL), relapsed/refractory primary mediastinal large B-cell lymphoma (PMBL), relapsed/refractory high-grade B-cell lymphomas with translocations of \textit{MYC} and \textit{BCL2} and/or \textit{BCL6} (Double/Triple Hit Lymphoma), and relapsed/refractory DLBCL.

External request
Submission request from Novartis: For the Panel to consider the inclusion of tisagenlecleucel as a treatment option for relapsed/refractory DLBCL, DLBCL arising from follicular lymphoma and high-grade B-cell lymphoma in the Guidelines.

Based on the FDA approval and panel discussion, the consensus was to include tisagenlecleucel for the following indications:

- Histologic transformation of FL to DLBCL only after treatment with \textgeq2 chemoimmunotherapy regimens including at least one anthracycline or anthracenedione-based regimen, unless contraindicated (FOLL-6 and FOLL-7)
- Relapsed/refractory DLBCL (BCEL-7 and BCEL-8)
- Relapsed/refractory PMBL (BCEL-B 1 of 3)
- Relapsed/refractory high-grade B-cell lymphomas with translocations of \textit{MYC} and \textit{BCL2} and/or \textit{BCL6} (Double/Triple Hit Lymphoma) (HGBL-1)

See Submission for references.